Abstract:Predicting antidepressant treatment response has been a clinical challenge for major depressive disorder (MDD). The inflammation hypothesis of depression suggests that cytokines play a key role in the pathophysiology of MDD and alterations in peripheral cytokine levels are associated with antidepressant treatment outcome. Present meta-analysis aimed to examine the association between baseline peripheral cytokine levels and the response to antidepressant treatment and to evaluate whether changes of cytokine levels were associated with the response to antidepressant treatment in patients with MDD. Human-based studies published in any language in peer-reviewed journals were systematically searched from the PubMed, Embase and Web of Science databases, from inception up to October 2018. The search terms included cytokine, depressive disorder and antidepressant and their synonyms. Case-control or case-case studies reporting on levels of IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, CRP, TNF-alpha, IFN-gamma, GM-CSF, MIP-1 alpha, and Eotaxin-1 in patients with MDD based on validated depression scales both before and after antidepressant treatment were included. Of 7408 identified records, 44 studies met inclusion. Standardized mean differences in each cytokine were evaluated, and random-effects meta-analyses were performed. MDD patients who responded to antidepressant treatment had lower baseline IL-8 levels than the nonresponders (Hedge's g = -0.28; 95%CI, -0.43 to -0.13; P = 0.0003; FDR = 0.004). Antidepressant treatment significantly decreased levels of TNF-alpha (Hedge's g = 0.60; 95%CI, 0.26-0.94; P = 0.0006; FDR = 0.004) only in responders, and responders showed significantly more decreased TNF-alpha levels compared with nonresponders (P = 0.046). These findings suggested that alterations in peripheral cytokine levels were associated with antidepressant treatment outcomes in MDD. Further investigations are warranted to elucidate sources of heterogeneity and examine the potentiality of using inflammatory cytokines as novel predictive markers for the pharmacological treatment of MDD.

The Changes In, and Relationship Between, Plasma Nitric Oxide and Corticotropin‐releasing Hormone in Patients with Major Depressive Disorder

Different Oxytocin and Corticotropin-Releasing Hormone System Changes in Bipolar Disorder and Major Depressive Disorder Patients

Association of Anhedonia with Brain-Derived Neurotrophic Factor and Interleukin-10 in Major Depressive Disorder

Increased Ratio of Mature BDNF to Precursor-Bdnf in Patients with Major Depressive Disorder with Severe Anhedonia.

Decreased Plasma Neuroactive Amino Acids and Increased Nitric Oxide Levels in Melancholic Major Depressive Disorder.

Nitric oxide synthase and nitric oxide alterations in chronically stressed rats: a model for nitric oxide in major depressive disorder.

Nitric Oxide Plasma Concentration Associated with Cognitive Impairment in Patients with Recurrent Depressive Disorder

Tumor Necrosis Factor- Variations in Patients With Major Depressive Disorder Before and After Antidepressant Treatment

Fluoxetine Treatment for Major Depression Decreases the Plasma Levels of Cytokines

Changes in the Serum Levels of Inflammatory Cytokines in Antidepressant Drug-Naïve Patients with Major Depression

Tumor Necrosis Factor-α Variations in Patients With Major Depressive Disorder Before and After Antidepressant Treatment

The Plasma IL-18, MIP-1α, MCP-1, SDF-1 and Rantes in Patients with Majior Depression

The relationship between plasma cytokine levels and antidepressant response in patients with first-episode major depressive disorder

Decreased NOS1 expression in the anterior cingulate cortex in depression.

Increased Hypocretin (orexin) Plasma Level in Depression, Bipolar Disorder Patients.

Combined Serum IL-6, C-reactive Protein, and Cortisol May Distinguish Patients with Anhedonia in Major Depressive Disorder.

The impact of ACTH levels on neurotransmitters and antioxidants in patients with major depressive disorder: A novel investigation

The Study of Level Changes of Serum Cytokine, C-reactive Protein and Zinc in Patients with Depression at Pre- and Post-Treatment of Paroxetine

Correlation Between the Plasma Cortisol Level and the Characteristics of Magnetic Resonance Spectroscopy of the Prefrontal Cortex and Hippocampus in Depressed Patients

Arginine metabolomics in mood disorders

Peripheral Cytokine Levels and Response to Antidepressant Treatment in Depression: a Systematic Review and Meta-Analysis